Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems.
10.3346/jkms.2014.29.1.53
- Author:
Hee Sang HWANG
1
;
Dok Hyun YOON
;
Cheolwon SUH
;
Chan Sik PARK
;
Jooryung HUH
Author Information
1. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. jrhuh@amc.seoul.kr
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma, Large B-Cell, Diffuse;
Intestines;
Stage;
Rituximab
- MeSH:
Adolescent;
Adult;
Aged;
Antibodies, Monoclonal, Murine-Derived/therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use;
Cyclophosphamide/therapeutic use;
Doxorubicin/therapeutic use;
Female;
Humans;
Immunologic Factors/therapeutic use;
Intestinal Neoplasms/*classification/drug therapy/mortality/surgery;
Lymphoma, Large B-Cell, Diffuse/*classification/drug therapy/mortality/surgery;
Male;
Middle Aged;
Neoplasm Staging/*methods;
Prednisone/therapeutic use;
Retrospective Studies;
Survival;
Survival Rate;
Treatment Outcome;
Vincristine/therapeutic use;
Young Adult
- From:Journal of Korean Medical Science
2014;29(1):53-60
- CountryRepublic of Korea
- Language:English
-
Abstract:
The gastrointestinal tract is the most common primary extranodal site for diffuse large B-cell lymphoma (DLBCL). However, there is no consensus on the most appropriate staging system for intestinal DLBCL. We evaluated the utility of the modified Ann Arbor system, the Lugano system, and the Paris staging system (a modification of the Tumor, Node, Metastases [TNM] staging for epithelial tumors) in 66 cases of resected intestinal DLBCL. The cases were treated with surgery, plus either cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy alone (n=26) or with the addition of rituximab immunotherapy (n=40). Median follow-up time was 40.4 months (range, 2.1-171.6 months). Fifty-six patients (84.8%) achieved complete remission. The overall 5-yr survival rate was 86.4% (57/66). Of the stage categories defined for each staging system, only the T stage of the Paris classification showed prognostic significance for overall survival by univariate analysis. However, none of the stage parameters was significantly correlated with patient survival on multivariate analysis. In conclusion, the results suggest that the T stage of the Paris classification system may be a prognostic indicator in intestinal DLBCL. The results also imply that in surgically resected intestinal DLBCL, the addition of rituximab to the CHOP regimen does not confer significant survival advantage.
